The motility of spermatozoa on 324 ejaculates was investigated with the help of two different methods, the sperm motile efficiency (Ishii) and a subjective calculation of the velocity of spermatozoa. Simultaneously the eosin-vitality-test was done. There was a very good statistical correlation (alpha = 0,1%) and no difference could be observed among the three methods. Ishii's sperm efficiency will be recommended as a standard.

Humans↗

PubMedDate not supplied

[The importance of rhodanide in the diagnosis of fertility disorders. I. Determination of rhodanide and its normal values in blood serum and ejaculate].

Explore the source record for details and available documents.

Adolescent↗

PubMedDate not supplied

[On the significance of Solcoseryl on fertility. 1. The effect of Solcoseryl on sperm motility in vitro].

The effect of different Solcoseryl (Solco, Basel, Switzerland) concentrations on the motility of human sperm were tested on 37 ejaculates taken from two subject groups. Altogether 111 motility studies were performed using the eosine vitality test. In view of the considerable variations associated with motility tests, Solcoseryl appeared to have no effect on sperm motility in the majority of cases in group 1. The observed improvement in motility (20%) was countered by still greater motility losses (27%). The results, obtained by studies on selected asthenospermia (group 2) are different, however: the 26% increase in motility was opposed to a motility loss of only 17%. A Solcoseryl concentration of 50% was found to have the best effects on motility. A general rise in sperm motility by means of Solcoseryl cannot be considered, although tests would appear advisable in isolated instances. Solcoseryl may be a valuable protective resuspension agent for insemination purposes.

Actihaemyl↗

PubMedDate not supplied

Importance of Solcoseryl in infertility. 2. Effects of Solcoseryl with pathological spermiogram findings in vivo.

44 patients with different spermiogram findings were treated with Solcoseryl¿ (Messrs. Solco, Basel, Switzerland). Among the findings were 39 cases of oligozoospermia, 26 cases of asthenozoospermia and 7 cases of hypospermia. 20 subjects had already received other treatment without success. Treatment in these 20 cases had been terminted at least six months prior to our studies. All patients received 10 injections comprising 1 ampule each of Solcoseryl¿ at intervals of 1 day with breaks at the weekends. The spermiograms were analysed upon completion of treatment and two weeks, four weeks, three months and six months after completion of treatment. The effects of Solcoseryl¿ proved to be completely independent of previous treatment. The most noticeable improvement in he findings following Solcoseryl¿ application was the sperm count. This effect was observed already upon completion of treatment and reached a maximum two weeks later. The effect then decreased. In a few cases, however, sperm numbers continued to decline for up to two weeks after therapy before subsequently increasing. The findings for 44% of the patients with asthenozoospermia were at least temporarily normal after the treatment. In a few of these patients, however, the number of dead sperm also increased immeditely after therapy. Severe cases of asthenozoospermia were not influenced by Solcoseryl¿ treatment. Improvement was also found in the case of hypospermia. In view of the objective improvement of the parameters of the ejaculate and the fact that gravidity has so far occurred in 11 (25%) of the wives of the patients treated with Solcoseryl¿ (in some cases after the first three-monthly examination), attempted treatment with Solcoseryl¿ is recommended.

Actihaemyl↗